Hikma's Dipyidamole ANDA074521 Receives AP Status from FDA
Hikma's ANDA074521 for Dipyidamole has received an Abbreviated Approval (AP) status from the FDA.
Therapeutic Area
Therapeutic area intelligence for Antiplatelet with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.